Overview

• A majority of Americans are skeptical about the effectiveness of weight loss drugs like Ozempic and Wegovy in significantly reducing the country's obesity rate.
• Goldman Sachs estimates that widespread adoption of GLP-1 agonists could add up to 1% to America's GDP, with a potential user base of 10 to 70 million by 2028.
• The FDA has approved Ozempic for managing Type 2 diabetes and Wegovy for long-term weight management, highlighting their medical credibility.
• Concerns over rising drug prices and counterfeit versions may deter potential users, despite the drugs' popularity.
• The debate over the role of genetics versus willpower in weight loss success continues, with 65% of Americans believing willpower alone is not enough for sustainable weight loss.